Core Insights - The article highlights the significant impact of the China International Import Expo (CIIE) in accelerating the application of innovative health technologies and products, showcasing the collaboration between multinational pharmaceutical companies and local Chinese enterprises [1][7]. Group 1: Innovative Products and Technologies - Medtronic's Micra series, the world's smallest clinically applied micro heart pacemaker, has been a star product at the CIIE, with its latest version receiving approval from the National Medical Products Administration in September 2023, expected to benefit Chinese patients soon [1]. - The first generation of Micra VR was introduced at the inaugural CIIE in 2018 and was quickly launched in China in 2019, now being used in over 800 hospitals [3]. - Pfizer showcased 17 innovative products that transitioned from the CIIE to clinical application, including a notable drug for specific late-stage lung cancer, which was first presented in 2019, approved in 2022, and has since benefited over 20,000 patients in China [5]. Group 2: Collaboration and Market Trends - The CIIE serves as a platform for multinational pharmaceutical companies to not only present cutting-edge technologies but also to initiate deep cooperation with local Chinese firms, reflecting a trend of collaborative innovation in the pharmaceutical industry [7]. - The event illustrates the growth of "China Intelligence" within the global research and development network, emphasizing the synergy between Chinese innovation and global health solutions [7].